Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 466

1.

A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.

Leacock SW, Basse AN, Chandler GL, Kirk AM, Rakheja D, Amatruda JF.

Dis Model Mech. 2012 Jan;5(1):95-106. doi: 10.1242/dmm.007401. Epub 2011 Oct 6.

2.

Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.

Jully B, Vijayalakshmi R, Gopal G, Sabitha K, Rajkumar T.

BMC Cancer. 2012 Nov 12;12:513. doi: 10.1186/1471-2407-12-513.

3.

The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.

Vural C, Uluoğlu O, Akyürek N, Oğuz A, Karadeniz C.

Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3. Epub 2011 Jan 26.

PMID:
21267687
4.

FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.

Yang L, Hu HM, Zielinska-Kwiatkowska A, Chansky HA.

Biochem Biophys Res Commun. 2010 Nov 5;402(1):129-34. doi: 10.1016/j.bbrc.2010.09.129. Epub 2010 Oct 8.

5.

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.

Boro A, Prêtre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, Schäfer BW, Niggli FK.

Int J Cancer. 2012 Nov 1;131(9):2153-64. doi: 10.1002/ijc.27472. Epub 2012 Mar 29.

6.

EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.

Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL.

Cancer Res. 2009 Dec 1;69(23):9047-55. doi: 10.1158/0008-5472.CAN-09-1540. Epub 2009 Nov 17.

7.

Promiscuous partnerships in Ewing's sarcoma.

Sankar S, Lessnick SL.

Cancer Genet. 2011 Jul;204(7):351-65. doi: 10.1016/j.cancergen.2011.07.008. Review.

8.

Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.

De Vito C, Riggi N, Suvà ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, Stamenkovic I.

PLoS One. 2011;6(8):e23592. doi: 10.1371/journal.pone.0023592. Epub 2011 Aug 10.

9.

Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.

Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL.

Cell Cycle. 2006 Dec;5(23):2753-9. Epub 2006 Dec 1.

PMID:
17172842
10.

A molecular function map of Ewing's sarcoma.

Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, Kovar H.

PLoS One. 2009;4(4):e5415. doi: 10.1371/journal.pone.0005415. Epub 2009 Apr 30.

11.

Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.

Uren A, Toretsky JA.

Future Oncol. 2005 Aug;1(4):521-8. Review.

PMID:
16556028
12.
13.
14.

EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.

Ban J, Siligan C, Kreppel M, Aryee D, Kovar H.

Adv Exp Med Biol. 2006;587:41-52. Review.

PMID:
17163154
15.

EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.

Hu HM, Zielinska-Kwiatkowska A, Munro K, Wilcox J, Wu DY, Yang L, Chansky HA.

J Orthop Res. 2008 Jun;26(6):886-93. doi: 10.1002/jor.20597.

16.

Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindán FJ, Barr FG, Ladanyi M.

Am J Pathol. 2000 Mar;156(3):849-55.

17.

Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).

Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM.

PLoS One. 2013 Jul 29;8(7):e68985. doi: 10.1371/journal.pone.0068985. Print 2013.

18.

Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Erkizan HV, Uversky VN, Toretsky JA.

Clin Cancer Res. 2010 Aug 15;16(16):4077-83. doi: 10.1158/1078-0432.CCR-09-2261. Epub 2010 Jun 14. Review.

19.

NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.

Kinsey M, Smith R, Lessnick SL.

Mol Cancer Res. 2006 Nov;4(11):851-9.

20.

High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM.

PLoS One. 2010 Nov 11;5(11):e13943. doi: 10.1371/journal.pone.0013943.

Items per page

Supplemental Content

Write to the Help Desk